5-N-BOC-氨基吲哚 | 184031-16-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-N-BOC-氨基吲哚
• 中文别名: 5-N-叔丁氧羰基-氨基吲哚；5-N-Boc-氨基吲哚
• 英文名称: tert-butyl (1H-indol-5-yl)carbamate
• 英文别名: Tert-butyl 1h-indol-5-ylcarbamate；tert-butyl N-(1H-indol-5-yl)carbamate
• CAS: 184031-16-1
• 化学式: C₁₃H₁₆N₂O₂
• 分子量: 232.282
• InChiKey: VGVLKMYJBZYCIS-UHFFFAOYSA-N

物化性质

• 沸点：
  350.4±15.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-N-BOC-氨基吲哚 在 吡啶 、 potassium carbonate 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.16h， 生成 1-(5-amino-1H-indol-3-yl)-2-(4-(4-fluorobenzyl)piperidin-1-yl)ethanone
  参考文献：
  名称：

  Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors

  摘要：

  A three-step synthetic pathway has been employed to synthesize a small library of 2-(4-arylpiperidin-1-yl)-1-(1H-indol-3-yl)ethanone and 2-(4-arylpiperidin-1-yl)-1-(1H-indol-3-yl) ethane-1,2-dione derivatives that have been screened in [H-3]ifenprodil competition binding assay. Some compounds exhibited significant binding affinity at nanomolar concentration, the most active being ligand 35 (IC50 = 5.5 nM). Docking experiments suggested the main interactions between 35 and GluN2B-containing NMDA receptors. Notably, the compound 35 reduced NMDA-mediated excitatory post-synaptic currents recorded in mouse hippocampal slices indicating antagonistic effects (50 nM). Moreover, the compound 35 has shown antioxidant effects in a preliminary screening, thus suggesting that it might be considered prototype for future drug development of novel 'dual target' neuroprotective agents. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.12.040
• 作为产物：
  描述：

  5-氨基吲哚 、 二碳酸二叔丁酯 以 乙酸乙酯 为溶剂， 反应 12.0h， 以95%的产率得到5-N-BOC-氨基吲哚
  参考文献：
  名称：

  原位组装的Ar-Rh(III)配合物催化游离(NH)-吲哚和吡咯的直接C-芳基化

  摘要：

  由 [RhCl(coe)2]2（coe = 顺式环辛烯）、[p-(CF3)C6H4]3P 和 CsOPiv 的反应原位组装的 Ar-Rh(III) 新戊酸酯配合物有效地催化了直接的 C-芳基化以高产率和高区域选择性分离游离 (NH)-吲哚和 (NH)-吡咯。该反应显示出优异的官能团相容性和低湿敏性。动力学研究支持一种机制，包括配合物 2（催化剂的静止状态）中的吲哚置换膦，然后是限速 CH 键金属化。

  DOI：

  10.1021/ja050279p

文献信息

• [EN] SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS<br/>[FR] SYNTHÈSE, PHARMACOLOGIE ET UTILISATION DE NOUVEAUX INHIBITEURS SÉLECTIFS DE LA TYROSINE KINASE 3 DE TYPE FMS FLT3 (FLT3)
  申请人：UNIV REGENSBURG

  公开号：WO2019034538A1

  公开（公告）日：2019-02-21

  The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.

  本发明涉及式(I)的小分子化合物及其作为FLT3抑制剂用于治疗各种疾病，如急性髓系白血病（AML）。本发明还涉及合成这些化合物的方法和治疗方法。
• Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents
  申请人：Ackermann Jean

  公开号：US20050096353A1

  公开（公告）日：2005-05-05

  This invention relates to compounds of the formula wherein one of R 6 , R 7 and R 8 is and X, Y 1 to Y 4 , R 1 to R 14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.

  这项发明涉及以下式的化合物 其中R 6 、R 7 和R 8 中的一个是 和X、Y 1 至Y 4 、R 1 至R 14 和n如描述中所定义的，并且所有的对映体和药用盐和/或酯。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防由PPARδ和/或PPARα激动剂调节的疾病。
• A Lewis Acid-Mediated Protocol for the Protection of Aryl Amines as their Boc-Derivatives
  作者：Giuseppe Bartoli、Letizia Sambri、Marcella Bosco、Manuela Locatelli、Enrico Marcantoni、Massimo Massaccesi、Paolo Melchiorre

  DOI：10.1055/s-2004-829059

  日期：——

  A new protocol of protection of poorly reactive aryl amines and functionalized amines with Boc2O in the presence of Zn(ClO4)2·6H2O as the catalyst is reported. The catalytic action of Zn(ClO4)2·6H2O is specific for the activation of the pyrocarbonates, thus acid sensitive functionalities and stereochemical configurations of the starting materials remain unaltered in the protection ­process.

  报道了一种新的保护低反应性芳胺和功能化胺的方案，使用Boc2O在Zn(ClO4)2·6H2O催化剂存在下进行保护。Zn(ClO4)2·6H2O的催化作用特异于激活焦碳酸盐，因此在保护过程中，起始材料的酸敏功能团和立体化学构型保持不变。
• Direct C-Arylation of Free (NH)-Indoles and Pyrroles Catalyzed by Ar−Rh(III) Complexes Assembled In Situ
  作者：Xiang Wang、Benjamin S. Lane、Dalibor Sames

  DOI：10.1021/ja050279p

  日期：2005.4.1

  Ar-Rh(III) pivalate complexes assembled in situ from the reaction of [RhCl(coe)2]2 (coe = cis-cyclooctene), [p-(CF3)C6H4]3P, and CsOPiv effectively catalyzed the direct C-arylation of free (NH)-indoles and (NH)-pyrroles in good yields and with high regioselectivity. The reaction displayed excellent functional group compatibility and low moisture sensitivity. Kinetics studies support a mechanism involving

  由 [RhCl(coe)2]2（coe = 顺式环辛烯）、[p-(CF3)C6H4]3P 和 CsOPiv 的反应原位组装的 Ar-Rh(III) 新戊酸酯配合物有效地催化了直接的 C-芳基化以高产率和高区域选择性分离游离 (NH)-吲哚和 (NH)-吡咯。该反应显示出优异的官能团相容性和低湿敏性。动力学研究支持一种机制，包括配合物 2（催化剂的静止状态）中的吲哚置换膦，然后是限速 CH 键金属化。
• [EN] BICYCLIC GPR119 MODULATORS<br/>[FR] MODULATEURS DE GPR119 BICYCLIQUES
  申请人：LUPIN LTD

  公开号：WO2012069917A1

  公开（公告）日：2012-05-31

  The present invention relates to compounds of Formula (I) that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and/or managing diseases, disorders syndromes or conditions associated with the modulation of GPR1 19 receptor by using either alone or in combinations of Formula (I).

  本发明涉及一种化合物（I）的公式，该化合物对治疗、预防和/或管理与调节GPR119受体活性相关的疾病、紊乱、综合征或病况有用。该发明还涉及制备这些化合物的方法、其药物组成物。此外，该发明还涉及利用单独或以公式（I）的组合物治疗、预防和/或管理与调节GPR119受体相关的疾病、紊乱、综合征或病况的方法。